Access Pharmaceuticals Inc., an emerging biopharmaceutical company, is focused on developing novel nanopolymer delivery technologies and products for cancer and dermatology. Currently, the company has one approved product, one product in phase 3 clinical development, four products in phase 2, and six products in preclinical development.

Dawson James recently posted an updated report on the company that establishes a “Speculative Buy” rating and $4.00 price target. The investment banking firm noted the fruits beginning to appear from the company’s successful folding in of two other publicly-traded biotech firms and believes there is more good news to come.

To access the complete research report, please visit the following link: http://www.dawsonjames.com/portal/ACCP_Update_7_6_09.pdf